OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results

Journal of the American Academy of Dermatology

Volumn 72, Issue 1, 2015, Pages 115-122

  Kimball, Alexa B ^a   Rothman, Kenneth J ^b   Kricorian, Gregory ^c   Pariser, David ^d   Yamauchi, Paul S ^e   Menter, Alan ^f   Teller, Craig F ^g   Aras, Girish ^c   Accortt, Neil A ^c   Hooper, Michele ^c   Rice, Kara Creamer ^c   Gelfand, Joel M ^h  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c AMGEN INC   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^e Skin Care Center   (United States)

^f BAYLOR RESEARCH INSTITUTE   (United States)

^g Bellaire Dermatology Associates   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adverse events; etanercept; infections; malignancy; plaque psoriasis; registry; safety; surveillance.

Indexed keywords

ETANERCEPT; IMMUNOGLOBULIN G; TUMOR NECROSIS FACTOR RECEPTOR;

APPENDICITIS; ARTICLE; BODY SURFACE; BRAIN CANCER; BRONCHITIS; CELLULITIS; COCCIDIOIDOMYCOSIS; CORONARY ARTERY DISEASE; DEMYELINATING NEUROPATHY; DERMATOLOGY LIFE QUALITY INDEX; DIVERTICULITIS; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FIBROSING ALVEOLITIS; FOLLOW UP; GASTROENTERITIS; HEART FAILURE; HEART INFARCTION; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; LUNG CANCER; LUPUS VULGARIS; LYMPHOMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; OPPORTUNISTIC INFECTION; OSTEOARTHRITIS; OSTEOMYELITIS; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL (TOPIC); PNEUMONIA; POSTMARKETING SURVEILLANCE; PSORIASIS; SEPSIS; STAPHYLOCOCCUS INFECTION; TUBERCULOSIS; ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; REGISTER; TIME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ETANERCEPT; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; TIME FACTORS; YOUNG ADULT;

EID: 84916917574     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.08.050     Document Type: Article

References (13)

1. Enbrel (etanercept) [prescribing information] 2013 Immunex Corp Thousand Oaks, CA
2. K.A. Papp, Y. Poulin, R. Bissonnette, M. Bourcier, D. Toth, and L. Rosoph Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population J Am Acad Dermatol 66 2012 e33 e45
3. A.B. Kimball, D. Pariser, P.S. Yamauchi, A. Menter, C.F. Teller, and Y. Shi OBSERVE-5, an observational post-marketing safety surveillance registry of etanercept for the treatment of psoriasis: a simple model for studying new psoriasis therapies Psoriasis Forum 16 2010 3 7
4. A.B. Kimball, D. Pariser, P.S. Yamauchi, A. Menter, C.F. Teller, and Y. Shi OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis J Am Acad Dermatol 68 2013 756 764
5. S.R. Feldman, and G.G. Krueger Psoriasis assessment tools in clinical trials Ann Rheum Dis 64 Suppl 2005 ii65 ii68
6. A.Y. Finlay, and G.K. Khan Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use Clin Exp Dermatol 19 1994 210 216
7. J.M. Gelfand, J. Wan, K. Callis Duffin, G.G. Krueger, R.E. Kalb, and J.D. Weisman Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting Arch Dermatol 148 2012 487 494
8. D.M. Pariser, C.L. Leonardi, K. Gordon, A.B. Gottlieb, S. Tyring, and K.A. Papp Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis J Am Acad Dermatol 67 2012 245 256
9. A.B. Gottlieb, K. Gordon, E.H. Giannini, P. Mease, J. Li, and Y. Chon Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications J Drugs Dermatol 10 2011 289 300
10. E.D. Dommasch, K. Abuabara, D.B. Shin, J. Nguyen, A.B. Troxel, and J.M. Gelfand The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials J Am Acad Dermatol 64 2011 1035 1050
11. K.A. Papp, J. Dekoven, L. Parsons, S. Pirzada, M. Robern, and L. Robertson Biologic therapy in psoriasis: perspectives on associated risks and patient management J Cutan Med Surg 16 2012 153 168
12. D. Margolis, W. Bilker, S. Hennessy, C. Vittorio, J. Santanna, and B.L. Strom The risk of malignancy associated with psoriasis Arch Dermatol 137 2001 778 783
13. J.M. Gelfand, D.B. Shin, A.L. Neimann, X. Wang, D.J. Margolis, and A.B. Troxel The risk of lymphoma in patients with psoriasis J Invest Dermatol 126 2006 2194 2201